Eagle Pharmaceuticals (NASDAQ:EGRX) reported Q1 2018 earnings this Morning, coming in at $0.53 per share, missing Wall Street’s estimates of $0.69 per Share. Revenue for the quarter came in at $46.60 million missing the streets estimates of $48.88 million Recent Insider Trading for Eagle Pharmaceuticals (NASDAQ:EGRX)
- On 3/6/2018 Sander A Flaum, Director, sold 2,340 with an average share price of $53.94 per share and the total transaction amounting to $126,219.60.
- On 8/16/2017 Pete A Meyers, CFO, bought 350 with an average share price of $55.45 per share and the total transaction amounting to $19,407.50.
- On 8/9/2017 Douglas L Braunstein, Director, bought 20,400 with an average share price of $49.07 per share and the total transaction amounting to $1,001,028.00.
- On 6/12/2017 Pete A Meyers, CFO, bought 350 with an average share price of $71.49 per share and the total transaction amounting to $25,021.50.
- On 5/19/2017 David Pernock, Insider, bought 255 with an average share price of $79.69 per share and the total transaction amounting to $20,320.95.
- On 5/16/2017 David Pernock, Insider, bought 200 with an average share price of $82.24 per share and the total transaction amounting to $16,448.00.
Dividend History for Eagle Pharmaceuticals (NASDAQ:EGRX)
Recent Trading for Eagle Pharmaceuticals (NASDAQ:EGRX) Shares of Eagle Pharmaceuticals closed the previous trading session at 59.00 down -1.13 1.88% with 59.0 shares trading hands.